Osaka Soda Co (4046) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
7 Aug, 2026Executive summary
Net sales for the first three months rose 18.4% year-on-year to ¥28,749 million, with all profit stages reaching record highs.
Operating profit increased 58.3% year-on-year to ¥6,235 million, ordinary profit rose 58.8% to ¥7,058 million, and profit attributable to owners of parent grew 62.3% to ¥4,947 million.
Launched the “Transform Our Future 2030” medium-term plan, focusing on business portfolio management, healthcare growth, new business creation, and management foundation strengthening.
ESG initiatives led to improved ESG scores and inclusion in the FTSE Blossom Japan Index.
Financial highlights
Gross profit for the quarter was ¥10,516 million, up from ¥7,782 million year-on-year.
Basic earnings per share increased to ¥40.49 from ¥24.22 year-on-year.
Comprehensive income for the quarter was ¥6,757 million, up from ¥3,283 million year-on-year.
Total assets as of June 30, 2026, were ¥170,999 million, up 1.3% from March 31, 2026.
Net assets increased to ¥130,448 million, with an equity-to-asset ratio of 76.3%.
Outlook and guidance
Full-year net sales forecast revised to ¥108,000 million, up 8.0% year-on-year.
Operating profit forecast for the year is ¥20,500 million, up 27.0% year-on-year.
Profit attributable to owners of parent projected at ¥14,800 million, up 4.3% year-on-year.
Basic earnings per share forecasted at ¥121.74 for the full year.
Dividend forecast revised to ¥30.00 per share for the year.
Latest events from Osaka Soda Co
- Operating profit jumped 41.7% on 7.6% higher sales, led by healthcare and functional chemicals.4046
Q2 202518 May 2026 - Profits and sales rose on strong healthcare and chemicals demand; stock split set for October.4046
Q1 202518 May 2026 - Profits surged on healthcare growth and supply recovery, with record highs forecast for FY2025 and FY2026.4046
Q4 202518 May 2026 - Profits surged on strong healthcare demand and supply recovery; full-year outlook maintained.4046
Q3 202518 May 2026 - Profits rose sharply despite lower sales, with upward guidance and enhanced shareholder returns.4046
Q2 202618 May 2026 - First-quarter profit rose 9.4% year-on-year, driven by healthcare and basic chemicals growth.4046
Q1 202618 May 2026 - Operating profit surged 21.6% and net profit rose 34.0% despite a 1.3% sales decline.4046
Q3 202618 May 2026 - Record profits and sales driven by Basic chemicals and Healthcare, with robust cash flow and new growth plans.4046
Q4 202618 May 2026